Restricted accessResearch articleFirst published online 2018-09
Variation in the Plasma Levels of Polyunsaturated Fatty Acids in Control vis-à-vis Nonalcoholic Fatty Liver Disease Subjects and Its Possible Association with Gut Microbiome
Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are becoming a major cause of chronic liver diseases globally. Polyunsaturated fatty acids (PUFA) have been postulated as a potential treatment for NAFLD. They can be obtained from diet and are also endogenously synthesized by enzymes delta-6-desaturase (D6D), delta-5-desaturase, and elongases. The current study is aimed at investigating the differences in the intake and levels of plasma PUFA between NAFLD patients and controls in Asian Indians. This correlation further propelled a pilot study to check for the differences in the gut microbiome of NASH subjects versus controls.
Methods:
One hundred forty-seven subjects were recruited and were grouped into healthy controls and cases. Subjects filled a food frequency questionnaire to assess PUFA intake. Plasma samples were subjected to gas chromatography analysis. For characterizing the gut microbiome, fecal samples of 20 NASH and healthy controls were analyzed by 16s rRNA gene sequencing. Alpha and beta diversity metrics and taxonomic analysis were carried out.
Results:
Plasma levels of eicosapentaenoic acid, γ-linoleic acid and D6D enzyme activity were significantly lower in cases. Dietary intake of total n-6 and n-3 PUFA did not differ between the two groups. Relative abundance of Streptococcus and Clostridium ramosum was significantly higher in NASH patients compared with healthy controls.
Conclusion:
This study demonstrates, for the first time, decreased D6D enzyme activity and plasma PUFA levels in NAFLD patients. Furthermore, it demonstrates gut dysbiosis in histologically proven NASH patients vis-à-vis healthy controls.
Get full access to this article
View all access options for this article.
References
1.
HazlehurstJM, TomlinsonJW. Non-alcoholic fatty liver disease in common endocrine disorders. Eur J Endocrinol, 2013; 169:R27–R37.
ZivkovicAM, GermanJB, SanyalAJ. Comparative review of diets for the metabolic syndrome: Implications for nonalcoholic fatty liver disease. Am J Clin Nutr, 2007; 86:285–300.
4.
MarchesiniG, BriziM, BianchiG, et al.Nonalcoholic fatty liver disease: A feature of the metabolic syndrome. Diabetes, 2001; 50:1844–1850.
5.
MisraA, KhuranaL. Obesity-related non-communicable diseases: South Asians vs White Caucasians. Int J Obes (Lond), 2011; 35:167–187.
6.
AmarapurkarDN, HashimotoE, LesmanaLA, et al.How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences?. J Gastroenterol Hepatol, 2007; 22:788–793.
7.
DiM, TufanoA, GarofanoT, et al.Polyunsaturated fatty acids, thrombosis and vascular disease. Pathophysiol Haemost Thromb, 2002; 32:361–364.
LeeJH, O'KeefeJH, LavieCJ, et al.Omega-3 fatty acids: Cardiovascular benefits, sources and sustainability. Nat Rev Cardiol, 2009; 6:753–758.
10.
O'KeefeJH, AbuissaH, SastreA, et al.Effects of omega-3 fatty acids on resting heart rate, heart rate recovery after exercise, and heart rate variability in men with healed myocardial infarctions and depressed ejection fractions. Am J Cardiol, 2006; 97:1127–1130.
11.
ArayaJ, RodrigoR, PettinelliP, et al.Decreased liver fatty acid Δ-6 and Δ-5 desaturase activity in obese patients. Obesity, 2009; 18:1460–1463.
12.
MussoG, GambinoR, De MichieliF, et al.Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology, 2003; 37:909–916.
13.
OyaJ, NakagamiT, SasakiS, et al.Intake of n-3 polyunsaturated fatty acids and non-alcoholic fatty liver disease: A cross-sectional study in Japanese men and women. Eur J Clin Nutr, 2010; 64:1179–1185.
14.
ZhengJ-S, XuA, HuangT, et al.Low docosahexaenoic acid content in plasma phospholipids is associated with increased non-alcoholic fatty liver disease in China. Lipids, 2012; 47:549–556.
15.
ChassaingB, GewirtzA. Gut microbiota, low-grade inflammation, and metabolic syndrome. Toxicol Pathol, 2014; 42:49–53.
16.
Abu-ShanabA, QuigleyEMM. The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol, 2010; 7:691–701.
ZhuL, BakerSS, GillC, et al.Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH. Hepatology, 2013; 57:601–609.
19.
PuscedduMM, El AidyS, CrispieF, et al.N-3 polyunsaturated fatty acids (PUFAs) reverse the impact of early-life stress on the gut microbiota. PLoS One, 2015; 10:1–13.
20.
MieleL, ValenzaV, La TorreG, et al.Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology, 2009; 49:1877–1887.
21.
CompareD, CoccoliP, RoccoA, et al.Gut-liver axis: The impact of gut microbiota on non alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis, 2012; 22:471–476.
22.
RastogiT, ReddyKS, VazM, et al.Diet and risk of ischemic heart disease in India. Am J Clin Nutr, 2004; 79:582–592.
23.
IngramMA, StonehouseW, RussellKG, et al.The New Zealand PUFA semiquantitative food frequency questionnaire is a valid and reliable tool to assess PUFA intakes in healthy New Zealand adults. J Nutr, 2012; 142:1968–1974.
24.
GlaserC, DemmelmairH, KoletzkoB. High-throughput analysis of total plasma fatty acid composition with direct in situ transesterification. PLoS One, 2010; 5:e12045.
25.
WangQ, GarrityGM, TiedjeJM, et al.Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. Appl Environ Microbiol, 2007; 73:5261–5267.
26.
SchlossPD, WestcottSL, RyabinT, et al.Introducing mothur: Open-source, platform-independent, community-supported software for describing and comparing microbial communities. Appl Environ Microbiol, 2009; 75:7537–7541.
27.
WangL, AthinarayananS, JiangG, et al.Fatty acid desaturase 1 (FADS1) gene polymorphisms control human hepatic lipid composition. NIH Public Access, 2016; 61:119–128.
28.
ArendtBM, ComelliEM, MaDWL, et al.Altered hepatic gene expression in non-alcoholic fatty liver disease is associated with lower hepatic n-3 and n-6 polyunsaturated fatty acids. Hepatology, 2015; 61:1565–1578.
29.
ManiI, KurpadAV. Fats & fatty acids in Indian diets: Time for serious introspection. Indian J Med Res, 2016; 144:507–514. DOI:10.4103/0971-5916.200904.
30.
DasUN. Biological significance of essential fatty acids. J Assoc Physicians India, 2006; 54:309–319.
31.
EmkenEA, AdlofRO, GulleyRM. Dietary linoleic acid influences desaturation and acylation of deuterium-labeled linoleic and linolenic acids in young adult males. Biochim Biophys Acta (BBA)/Lipids Lipid Metab, 1994; 1213:277–288.
32.
HariziH, CorcuffJB, GualdeN. Arachidonic-acid-derived eicosanoids: Roles in biology and immunopathology. Trends Mol Med, 2008; 14:461–469.
33.
SchmitzG, EckerJ. The opposing effects of n-3 and n-6 fatty acids. Prog Lipid Res, 2008; 47:147–155.
34.
PattersonE, WallR, FitzgeraldGF, et al.Health implications of high dietary omega-6 polyunsaturated fatty acids. J Nutr Metab, 2012; 2012:1–16.
35.
ArayaJ, RodrigoR, VidelaLA, et al.Increase in long-chain polyunsaturated fatty acid n-6/n-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci, 2004; 106:635–643.
36.
VernekarM, AmarapurkarD, JoshiK, et al.Gene polymorphisms of desaturase enzymes of polyunsaturated fatty acid metabolism and adiponutrin and the increased risk of nonalcoholic fatty liver disease. Meta Gene, 2017; 11:152–156.
37.
KaliannanK, WangB, LiX-Y, et al.Omega-3 fatty acids prevent early-life antibiotic exposure-induced gut microbiota dysbiosis and later-life obesity. Int J Obes, 2016; 40:1039–1042.
38.
TremaroliV, BäckhedF. Functional interactions between the gut microbiota and host metabolism. Nature, 2012; 489:242–249.
39.
CaniPD, AmarJ, IglesiasMA, et al.Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes, 2007; 56:1761–1772.
40.
CaniPD, PossemiersS, Van de WieleT, et al.Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut, 2009; 58:1091–1103.
41.
MouzakiM, ComelliEM, ArendtBM, et al.Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology, 2013; 58:120–127.
42.
JumpertzR, LeDS, TurnbaughPJ, et al.Energy-balance studies reveal associations between gut microbes, caloric load, and nutrient absorption in humans. Am J Clin Nutr, 2011; 94:58–65.
43.
ZhuL, BakerRD, BakerSS. Gut microbiome and nonalcoholic fatty liver diseases. Pediatr Res, 2015; 77:245–251.
44.
Al-jashamyK, MuradA, ZeehaidaM, et al.Prevalence of colorectal cancer associated with Streptococcus bovis among inflammatory bowel and chronic gastrointestinal tract disease patients. Asian Pac J Cancer Prev, 2010; 11:1765–1768.
45.
NakaS, NomuraR, TakashimaY, et al.A specific Streptococcus mutans strain aggravates non-alcoholic fatty liver disease. Oral Dis, 2014; 20:700–706.
46.
WotingA, PfeifferN, LohG, et al.Clostridium ramosum promotes high-fat diet-induced obesity in gnotobiotic mouse models. MBio, 2014; 5:e01530-14.
47.
RamanM, AhmedI, GillevetPM, et al.Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol, 2013; 11:868–875.e1-3.
48.
ScheppachW, WeilerF. The butyrate story: Old wine in new bottles?. Curr Opin Clin Nutr Metab Care, 2004; 7:563–567.
49.
KlesKA, ChangEB. Short-chain fatty acids impact on intestinal adaptation, inflammation, carcinoma, and failure. Gastroenterology, 2006; 130(2 Suppl 1):100–105.
50.
VinoloMAR, RodriguesHG, NachbarRT, et al.Regulation of inflammation by short chain fatty acids. Nutrients, 2011; 3:858–876.
51.
PattersonE, O' DohertyRM, MurphyEF, et al.Impact of dietary fatty acids on metabolic activity and host intestinal microbiota composition in C57BL/6J mice. Br J Nutr, 2014; 111:1–13.
52.
KaliannanK, WangB, LiX-Y, et al.A host-microbiome interaction mediates the opposing effects of omega-6 and omega-3 fatty acids on metabolic endotoxemia. Sci Rep, 2015; 5:11276.
53.
SpencerMD, HampTJ, ReidRW, et al.Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency. Gastroenterology, 2011; 140:976–986.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
